Previous 10 | Next 10 |
Two winners will be awarded 40 human plasma or serum samples to be processed on the SomaScan ® Platform at Genomax’s Singapore lab SINGAPORE & BOULDER, Colo., May 07, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a global leader in proteomics technology, today anno...
BOULDER, Colo., April 20, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that it will report financial results for the first quarter 2023 after market close on Thursday, May 11, 2023. Management will host a corresponding conference call beginning at 4...
Adam Taich, EVP Life Sciences, promoted to interim CEO with a focus on operational execution Board transition adds industry veterans: Jason Ryan as Chairman; Tycho Peterson, Kathy Hibbs, and Tom Carey as Independent Directors Fourth quarter 2022 revenue of $18.8 million; full ye...
BOULDER, Colo., March 13, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, recently completed the 7,000-plex assay on and delivered data for 4,000 plasma samples from the China Kadoorie Biobank (CKB), one of the world’s largest prospective studies. The SomaLogic...
BOULDER, Colo., March 09, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that it will report financial results for the fourth quarter and full year 2022 after market close on Tuesday, March 28, 2023. Company management will host a corresponding confer...
BOULDER, Colo., Jan. 31, 2023 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced the expansion of its SomaLogic™ Certified Site program through a recently-launched, world-class proteomics initiative with Group 42 Healthcare (G42), a...
BOULDER, Colo., Jan. 09, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that preliminary, unaudited revenue for the full year 2022 is expected to be at the high end of its guidance range of $93 to $98 million, reflecting approximately 20% year-over-ye...
SomaLogic, CM Life Sciences II (NASDAQ:CMII) and Twist Bioscience (NASDAQ:TWST) announce a collaboration aimed at creating novel antibodies and enabling innovative drug discovery based on key disease biomarkers. The collaboration will allow Twist to use the SomaScan Platfo...
Proteomics has the potential to revolutionize medicine in potentially the same way that genomics has. The traditional field looks primed for disruption and that effort could hit critical mass soon. Quantum-Si has set forth a business plan to utilize consumables as the primary driver o...
A team with a track record of prior success has raised its largest SPAC yet. The SPAC is about two months old, meaning it is becoming more likely to do a deal going forward. Because of the track record and the reputation of the team, the warrants are trading relatively rich. ...
News, Short Squeeze, Breakout and More Instantly...
CM Life Sciences II Inc. Company Name:
CMII Stock Symbol:
NASDAQ Market:
BOULDER, Colo., Sept. 05, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, announced today that it is extending its collaborative agreement with global healthcare innovator, Novo Nordisk. As part of the agreement, which now extends into the end of 2025, Novo Nordisk wi...
Revenue of $20.5 million, an increase of 45% year-over-year Cash and investments of approximately $474 million, a strong capital position to fund current and future business initiatives Reiterating full year 2023 revenue guidance and operating expense target Management to host confere...
BOULDER, Colo., July 24, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that it will report financial results for the second quarter 2023 after market close on August 14 th , 2023. Management will host a corresponding conference call beginning at ...